What makes someone leap without looking? What drives a person to risk everything? This season, we’re diving deep into the moments that define us—the split-second decisions, the life-changing gambles, the quiet acts of rebellion that reshape everything.

GET TICKETS!

Every Mainstage will feature five unique voices sharing true stories of bold risks, brave confessions, and moments that required everything they had. Stories that will make you laugh, cry, gasp, and maybe cover your eyes. Bold choices. Audacious proclamations. Courageous humility.

Join us as five storytellers take the stage and challenge what it means to be DARING.

ON SALE NOW

New York, NY
Symphony Space
September 18th

BUY TICKETS

San Francisco, CA
Herbst Theatre
September 18th

BUY TICKETS

Toronto, Canada
Koerner Hall

September 18th

BUY TICKETS

New Haven, CT
College Street Music Hall
September 25th

BUY TICKETS

London, UK
Union Chapel
September 26th

BUY TICKETS

Honolulu, HI Mainstage
Hawaii Theatre Center
October 3rd

BUY TICKETS

New Brunswick, NJ
State Theatre New Jersey
October 17th

BUY TICKETS

Boston, MA
The Wilbur
October 29th

BUY TICKETS

Nairobi, Kenya
Catholic University of
Eastern Africa
November 1st

BUY TICKETS

Philadelphia, PA
Miller Theater
November 7th

BUY TICKETS

Tulsa, OK
Cain’s Ballroom
November 19th

BUY TICKETS

Chicago, IL
Auditorium Theatre
November 20th

BUY TICKETS

Atlanta, GA
Center Stage
December 4th

BUY TICKETS

Portland, OR
Arlene Schnitzer Concert Hall
December 9th

BUY TICKETS

Austin, TX
Paramount Theatre
December 10th

BUY TICKETS

–

ON SALE SOON

Kansas City, MO
Folly Theater
October 17th

New York, NY
El Museo Del Barrio
October 24th

New York, NY
St. Ann & the
Holy Trinity Church
December 5th

FIND EVENTS NEAR YOU

More From The Moth

The Moth’s podcast feed presents episodes of The Peabody Award-winning Moth Radio Hour and original episodes of The Moth Podcast.

LISTEN NOW

Membership Perk: Complimentary Tickets!

Become a Luna Member and receive two complimentary in-person tickets to a Moth Mainstage! Additional benefits include presale access to StorySLAMs, reserved seating, and storytelling workshops. Plus, join before August 31st to get two extra months of benefits, free!

LEARN MORE

What makes someone leap without looking? What drives a person to risk everything? This season, we’re diving deep into the moments that define us—the split-second decisions, the life-changing gambles, the quiet acts of rebellion that reshape everything.

GET TICKETS!

Every Mainstage will feature five unique voices sharing true stories of bold risks, brave confessions, and moments that required everything they had. Stories that will make you laugh, cry, gasp, and maybe cover your eyes. Bold choices. Audacious proclamations. Courageous humility.

Join us as five storytellers take the stage and challenge what it means to be DARING.

ON SALE NOW

New York, NY
Symphony Space
September 18th

BUY TICKETS

San Francisco, CA
Herbst Theatre
September 18th

BUY TICKETS

Toronto, Canada
Koerner Hall

September 18th

BUY TICKETS

New Haven, CT
College Street Music Hall
September 25th

BUY TICKETS

London, UK
Union Chapel
September 26th

BUY TICKETS

Honolulu, HI Mainstage
Hawaii Theatre Center
October 3rd

BUY TICKETS

New Brunswick, NJ
State Theatre New Jersey
October 17th

BUY TICKETS

Boston, MA
The Wilbur
October 29th

BUY TICKETS

Nairobi, Kenya
Catholic University of
Eastern Africa
November 1st

BUY TICKETS

Philadelphia, PA
Miller Theater
November 7th

BUY TICKETS

Tulsa, OK
Cain’s Ballroom
November 19th

BUY TICKETS

Chicago, IL
Auditorium Theatre
November 20th

BUY TICKETS

Atlanta, GA
Center Stage
December 4th

BUY TICKETS

Portland, OR
Arlene Schnitzer Concert Hall
December 9th

BUY TICKETS

Austin, TX
Paramount Theatre
December 10th

BUY TICKETS

–

ON SALE SOON

Kansas City, MO
Folly Theater
October 17th

New York, NY
El Museo Del Barrio
October 24th

New York, NY
St. Ann & the
Holy Trinity Church
December 5th

FIND EVENTS NEAR YOU

More From The Moth

The Moth’s podcast feed presents episodes of The Peabody Award-winning Moth Radio Hour and original episodes of The Moth Podcast.

LISTEN NOW

Membership Perk: Complimentary Tickets!

Become a Luna Member and receive two complimentary in-person tickets to a Moth Mainstage! Additional benefits include presale access to StorySLAMs, reserved seating, and storytelling workshops. Plus, join before August 31st to get two extra months of benefits, free!

LEARN MORE

Read Online

A Note From the Founder

I’m bothered by the lack of distinction between generative AI and non-generative AI (also called traditional machine learning, traditional AI, analytical AI) in nearly all AI coverage and commentary.

Collapsing different types of AI into one term, “AI,” promotes confusion and misinformation about what we really need to pay attention to and be concerned about. When products, for example, are described as “using AI” or “having AI,” it tells me nothing about what is actually being used or whether there are ethical issues involved, e.g., theft of creators’ works by gen AI.

Continue reading on LinkedIn >

Read Online

A Note From the Founder

I’m bothered by the lack of distinction between generative AI and non-generative AI (also called traditional machine learning, traditional AI, analytical AI) in nearly all AI coverage and commentary.

Collapsing different types of AI into one term, “AI,” promotes confusion and misinformation about what we really need to pay attention to and be concerned about. When products, for example, are described as “using AI” or “having AI,” it tells me nothing about what is actually being used or whether there are ethical issues involved, e.g., theft of creators’ works by gen AI.

Continue reading on LinkedIn >

Groundbreaking research led by a Swansea University academic has revealed a synthetic glycosystem – a sugar-coated polymer nanoparticle – that can block Covid-19 from infecting human cells, reducing infection rates by nearly 99%.

The glycosystem is a specially designed particle that mimics natural sugars found on human cells. These sugars, known as polysialosides, are made of repeating units of sialic acid – structures that viruses often target to begin infection. By copying this structure, the synthetic molecule acts as a decoy, binding to the virus’s spike protein and preventing it from attaching to real cells.

Unlike vaccines, which trigger immune responses, this molecule acts as a physical shield, offering a novel approach to infection prevention.

Using advanced lab techniques to measure molecular interactions and simulate virus binding, researchers found that the glycosystem binds to the virus 500 times more strongly than a similar compound containing sulphates but no sugars. It was also effective at very low doses and worked against both the original SARS-CoV-2 strain and the more infectious D614G variant.

Tests on human lung cells showed a 98.6% reduction in infection when the molecule was present. Crucially, the research highlighted that its effectiveness stems not just from its charge, but from its precise sugar structure – giving this glycosystem its powerful infection-blocking capability.

The discovery is the result of collaboration between Swansea University, Freie Universität Berlin, and Charité – Universitätsmedizin Berlin.

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook Compilation of the top interviews, articles, and news in the last year.Download the latest edition

As the main corresponding author and research supervisor, Dr Sumati Bhatia, Senior Lecturer in Chemistry at Swansea University, said: “Leading this research, alongside our international partners, has been incredibly rewarding. It opens a new direction for using glycosystems as a therapeutic strategy against SARS-CoV-2 and could lay the foundation for a new class of antiviral therapies to protect those most at risk.”

The team is now preparing for further biological testing in high-containment laboratories to assess the molecule’s effectiveness against multiple virus strains.

T

his breakthrough could pave the way for antiviral nasal sprays, surface disinfectants, and treatments to protect vulnerable groups, offering a new line of defense against Covid-19 and future pandemics.

Source:

Swansea University

Journal reference:

Khatri, V., et al. (2025). Polysialosides Outperform Sulfated Analogs for Binding with SARS-CoV-2. Small. doi.org/10.1002/smll.202500719.

Groundbreaking research led by a Swansea University academic has revealed a synthetic glycosystem – a sugar-coated polymer nanoparticle – that can block Covid-19 from infecting human cells, reducing infection rates by nearly 99%.

The glycosystem is a specially designed particle that mimics natural sugars found on human cells. These sugars, known as polysialosides, are made of repeating units of sialic acid – structures that viruses often target to begin infection. By copying this structure, the synthetic molecule acts as a decoy, binding to the virus’s spike protein and preventing it from attaching to real cells.

Unlike vaccines, which trigger immune responses, this molecule acts as a physical shield, offering a novel approach to infection prevention.

Using advanced lab techniques to measure molecular interactions and simulate virus binding, researchers found that the glycosystem binds to the virus 500 times more strongly than a similar compound containing sulphates but no sugars. It was also effective at very low doses and worked against both the original SARS-CoV-2 strain and the more infectious D614G variant.

Tests on human lung cells showed a 98.6% reduction in infection when the molecule was present. Crucially, the research highlighted that its effectiveness stems not just from its charge, but from its precise sugar structure – giving this glycosystem its powerful infection-blocking capability.

The discovery is the result of collaboration between Swansea University, Freie Universität Berlin, and Charité – Universitätsmedizin Berlin.

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook Compilation of the top interviews, articles, and news in the last year.Download the latest edition

As the main corresponding author and research supervisor, Dr Sumati Bhatia, Senior Lecturer in Chemistry at Swansea University, said: “Leading this research, alongside our international partners, has been incredibly rewarding. It opens a new direction for using glycosystems as a therapeutic strategy against SARS-CoV-2 and could lay the foundation for a new class of antiviral therapies to protect those most at risk.”

The team is now preparing for further biological testing in high-containment laboratories to assess the molecule’s effectiveness against multiple virus strains.

T

his breakthrough could pave the way for antiviral nasal sprays, surface disinfectants, and treatments to protect vulnerable groups, offering a new line of defense against Covid-19 and future pandemics.

Source:

Swansea University

Journal reference:

Khatri, V., et al. (2025). Polysialosides Outperform Sulfated Analogs for Binding with SARS-CoV-2. Small. doi.org/10.1002/smll.202500719.